REG - Iconic Labs PLC - Conversion of Securities

Iconic LabsAnnouncement

04/09/2023 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230904:nRSD2966La&default-theme=true

RNS Number : 2966L  Iconic Labs PLC  04 September 2023

Iconic Labs PLC

 

("Iconic" or the "Company")

 

Conversion of Notes and Allotment of Shares

 

Iconic Labs PLC (LSE:ICON), announces that it has received a valid Conversion
Notice from the European High Growth Opportunities Securitization Fund.

 

The Conversion Notice was dated 1 September 2023 and provides for 50
Convertible Notes to be converted into 220,361 ordinary shares of £0.1 in the
Company ("Ordinary Shares") at a conversion price of £0.2269 at the aggregate
principal amount of £50,000.

Application is being made for 220,361 new Ordinary Shares to be admitted to
trading on the Main Market of the London Stock Exchange which is expected to
be on or around 8 September 2023. These shares rank pari passu with the
existing Ordinary Shares of the Company.

Following the issue of these shares, the Company's issued ordinary share
capital shall consist of 4,920,019 Ordinary Shares. The figure of 4,920,019
represents the total voting rights in the Company and should be used by
shareholders as the denominator for the calculation by which they can
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the Financial Conduct Authority's
Disclosure Guidance & Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic
law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

For any further information or enquiries please contact:

 

ir@iconiclabs.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CONEAFNLEEFDEFA